{"id":2826,"date":"2025-03-06T09:07:53","date_gmt":"2025-03-06T09:07:53","guid":{"rendered":"https:\/\/mrikpa.org.uk\/?p=2826"},"modified":"2026-04-14T11:59:20","modified_gmt":"2026-04-14T10:59:20","slug":"nice-rejects-sparsentan-for-iga-nephropathy-what-it-means-for-kidney-patients","status":"publish","type":"post","link":"https:\/\/mrikpa.org.uk\/nice-rejects-sparsentan-for-iga-nephropathy-what-it-means-for-kidney-patients\/","title":{"rendered":"NICE Rejects Sparsentan for IgA Nephropathy: What It Means for Kidney Patients"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"2826\" class=\"elementor elementor-2826\" data-elementor-post-type=\"post\">\n\t\t\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" class=\"elementor-element elementor-element-2b8b5bc0 e-flex e-con-boxed e-con e-parent\" data-id=\"2b8b5bc0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5b2e6094 elementor-widget elementor-widget-text-editor\" data-id=\"5b2e6094\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><strong>Kidney Advocacy Groups Disappointed by Draft NICE Decision<\/strong><\/p><p>A recent draft decision by the National Institute for Health and Care Excellence (<a href=\"https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11359\/consultation\/html-content-5\" target=\"_blank\" rel=\"noopener\">NICE<\/a>) has caused frustration among kidney patients and advocacy groups. On March 4, 2025, NICE announced that it would not approve <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(23)00569-X\/abstract\" target=\"_blank\" rel=\"noopener\">Sparsentan<\/a>, a promising new treatment for <a href=\"https:\/\/www.kidney.org\/kidney-topics\/iga-nephropathy\" target=\"_blank\" rel=\"noopener\">IgA nephropathy (IgAN)<\/a>, for NHS funding at this stage.<\/p><p>This decision comes as a setback for patients living with IgA nephropathy, a progressive form of chronic kidney disease (CKD), who had hoped that Sparsentan could provide a new treatment option to slow kidney damage and delay dialysis or transplant.<\/p><p>While the decision is not yet final, it raises concerns about how new treatments for kidney disease are assessed and made available on the NHS.<\/p><p><strong>What Is IgA Nephropathy and Why Is Treatment Important?<\/strong><\/p><p>IgA nephropathy (IgAN) is a rare autoimmune kidney disease where immunoglobulin A (IgA) builds up in the kidneys, causing inflammation and long-term damage. Over time, this can lead to kidney failure, requiring dialysis or a kidney transplant.<\/p><p>Current kidney disease treatment for IgAN includes blood pressure medications, steroids, and lifestyle changes, but they do not work for everyone. Many patients have been waiting for new kidney disease medications that can more effectively slow the progression of the condition.<\/p><p><strong>Why Was Sparsentan Rejected?<\/strong><\/p><p>Sparsentan is a dual endothelin and angiotensin receptor antagonist (DEARA) that has been shown in clinical trials to reduce proteinuria (protein in urine)\u2014a key sign of kidney damage\u2014and slow the progression of IgA nephropathy.<\/p><p>Despite its potential benefits, NICE\u2019s draft guidance states that the drug does not currently meet NHS cost-effectiveness thresholds. This means that, as things stand, sparsentan will not be made available through NHS kidney treatment pathways.<\/p><p>However, kidney patient advocacy groups like Kidney Research UK have urged NICE to reconsider, highlighting the urgent need for more effective kidney disease treatments and the lack of options currently available for IgA nephropathy patients in the UK.<\/p><p><strong>What Happens Next?<\/strong><\/p><p>NICE will review further evidence and feedback before making its final decision. Kidney charities and patient representatives will continue to advocate for improved access to kidney disease medications like Sparsentan.<\/p><p>For now, patients with IgA nephropathy should continue working with their renal consultants to explore available kidney disease treatment options.<\/p><p>MRIKPA will continue to monitor updates on NICE\u2019s decision regardingSparsentan and provide information on new developments.<\/p><p>Stay informed, get involved &#8211; <a href=\"https:\/\/mrikpa.org.uk\/become-a-member\">Join MRIKPA today<\/a><\/p><p>For more kidney health research and to stay updated on IgA Nephropathy treatments, visit our <a href=\"https:\/\/mrikpa.org.uk\/research-and-news\">Latest News &amp; Updates<\/a> page<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" class=\"elementor-element elementor-element-063b60a e-flex e-con-boxed e-con e-parent\" data-id=\"063b60a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-55d092a elementor-widget elementor-widget-n-accordion\" data-id=\"55d092a\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-8990\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-8990\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> What is Sparsentan? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8990\" class=\"elementor-element elementor-element-4ac6e3c e-con-full e-flex e-con e-child\" data-id=\"4ac6e3c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8990\" class=\"elementor-element elementor-element-b648b58 e-flex e-con-boxed e-con e-child\" data-id=\"b648b58\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-581fe2d elementor-widget elementor-widget-text-editor\" data-id=\"581fe2d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">Sparsentan is a<strong>\u00a0medication for IgA nephropathy (IgAN)<\/strong> that works by <strong>reducing proteinuria (protein in urine)<\/strong>and protecting kidney function. It has shown promise in <strong>slowing the progression of chronic kidney disease (CKD)<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-8991\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-8991\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Why is sparsentan important for IgA nephropathy patients? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8991\" class=\"elementor-element elementor-element-9a99e83 e-con-full e-flex e-con e-child\" data-id=\"9a99e83\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8991\" class=\"elementor-element elementor-element-4fe491d e-flex e-con-boxed e-con e-child\" data-id=\"4fe491d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9652156 elementor-widget elementor-widget-text-editor\" data-id=\"9652156\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">Unlike many other <strong>kidney disease medications<\/strong>, Sparsentan directly targets <strong>both endothelin and angiotensin receptors<\/strong>, which play a key role in <strong>IgA nephropathy progression<\/strong>. Clinical trials showed it could significantly <strong>slow kidney damage<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-8992\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"3\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-8992\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Why are NICE considering rejecting Sparsentan? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8992\" class=\"elementor-element elementor-element-540bf2c e-con-full e-flex e-con e-child\" data-id=\"540bf2c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8992\" class=\"elementor-element elementor-element-c3b85cd e-flex e-con-boxed e-con e-child\" data-id=\"c3b85cd\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-15876eb elementor-widget elementor-widget-text-editor\" data-id=\"15876eb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">NICE\u2019s <strong>draft decision<\/strong> states that the drug\u2019s <strong>cost-effectiveness<\/strong> does not currently meet the NHS\u2019s funding criteria. However, further reviews and <strong>kidney patient advocacy efforts<\/strong> may influence the final decision.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-8993\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"4\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-8993\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Is the NICE decision final? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8993\" class=\"elementor-element elementor-element-74c1d59 e-con-full e-flex e-con e-child\" data-id=\"74c1d59\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8993\" class=\"elementor-element elementor-element-5b91612 e-flex e-con-boxed e-con e-child\" data-id=\"5b91612\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e41a22d elementor-widget elementor-widget-text-editor\" data-id=\"e41a22d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">No, this is a <strong>draft ruling<\/strong>. Further consultation and advocacy efforts may impact NICE\u2019s final recommendation.\u00a0<\/p><p data-pm-slice=\"1 1 []\">Visit the NICE webpage about the project to read the committee papers <a href=\"https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11359\/documents\" target=\"_blank\" rel=\"noopener\">HERE<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-8994\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"5\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-8994\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Can I still access sparsentan in the UK? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8994\" class=\"elementor-element elementor-element-efaa9c5 e-con-full e-flex e-con e-child\" data-id=\"efaa9c5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8994\" class=\"elementor-element elementor-element-3efbc9f e-flex e-con-boxed e-con e-child\" data-id=\"3efbc9f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-24213a1 elementor-widget elementor-widget-text-editor\" data-id=\"24213a1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">At this stage, <strong>sparsentan is not available through NHS kidney treatment pathways<\/strong>. Some patients may be able to access it through <strong>clinical trials or private healthcare<\/strong>.<\/p><p data-pm-slice=\"1 1 []\">\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-8995\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"6\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-8995\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> What should I do if I have IgA nephropathy? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8995\" class=\"elementor-element elementor-element-fc0b1ed e-con-full e-flex e-con e-child\" data-id=\"fc0b1ed\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" role=\"region\" aria-labelledby=\"e-n-accordion-item-8995\" class=\"elementor-element elementor-element-d300e03 e-flex e-con-boxed e-con e-child\" data-id=\"d300e03\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4312d7c elementor-widget elementor-widget-text-editor\" data-id=\"4312d7c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">If you have <strong>IgA nephropathy<\/strong>, talk to your <strong>renal consultant<\/strong> about the best available <strong>kidney disease treatments<\/strong>. You can also support advocacy efforts to <strong>help improve access to new kidney medications in the UK<\/strong>.<\/p><p data-pm-slice=\"1 1 []\">\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div data-particle_enable=\"false\" data-particle-mobile-disabled=\"false\" class=\"elementor-element elementor-element-8955121 e-flex e-con-boxed e-con e-parent\" data-id=\"8955121\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8324807 elementor-widget elementor-widget-text-editor\" data-id=\"8324807\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>\u00a0<\/p><p><em>Learn more about IgA Nephropathy on the Kidney Research UK Website: <a href=\"https:\/\/www.kidneyresearchuk.org\/conditions-symptoms\/iga-nephropathy\/#:~:text=IgA%20nephropathy%20(IgAN)%20is%20a,detectable%20through%20a%20urine%20test.\" target=\"_blank\" rel=\"noopener\">HERE<\/a><\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>NICE has rejected sparsentan for IgA nephropathy patients in England due to cost-effectiveness concerns. We explain what this means and what treatment options remain for people living with IgA nephropathy.<\/p>\n","protected":false},"author":3,"featured_media":2827,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[87,155,154,166,157,164,163,158,165,161,160,162,159],"class_list":["post-2826","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-research","tag-87","tag-chronic-kidney-disease","tag-ckd","tag-filspari","tag-iga-nephropathy-igan","tag-iga-nephropathy-research","tag-kidney-disease-medication","tag-kidney-disease-treatment","tag-kidney-health-uk","tag-kidney-patient-advocacy","tag-new-treatments-for-kidney-disease","tag-nhs-kidney-treatment","tag-sparsentan-nice-decision"],"_links":{"self":[{"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/posts\/2826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/comments?post=2826"}],"version-history":[{"count":12,"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/posts\/2826\/revisions"}],"predecessor-version":[{"id":4451,"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/posts\/2826\/revisions\/4451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/media\/2827"}],"wp:attachment":[{"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/media?parent=2826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/categories?post=2826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mrikpa.org.uk\/wp-json\/wp\/v2\/tags?post=2826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}